192 related articles for article (PubMed ID: 18723487)
1. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.
Veltkamp SA; Pluim D; van Eijndhoven MA; Bolijn MJ; Ong FH; Govindarajan R; Unadkat JD; Beijnen JH; Schellens JH
Mol Cancer Ther; 2008 Aug; 7(8):2415-25. PubMed ID: 18723487
[TBL] [Abstract][Full Text] [Related]
2. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
Veltkamp SA; Pluim D; van Tellingen O; Beijnen JH; Schellens JH
Drug Metab Dispos; 2008 Aug; 36(8):1606-15. PubMed ID: 18490432
[TBL] [Abstract][Full Text] [Related]
3. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
Hodge LS; Taub ME; Tracy TS
Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU).
Tiefenthaler M; Hohla F; Irschick E; Strasser-Wozak E; Bacher N; Mühlmann O; Wein W; Konwalinka G
Immunobiology; 2003; 207(2):149-57. PubMed ID: 12675273
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography.
Yilmaz B; Kadioğlu YY; Aksoy Y
Anal Biochem; 2004 Sep; 332(2):234-7. PubMed ID: 15325290
[TBL] [Abstract][Full Text] [Related]
6. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
[TBL] [Abstract][Full Text] [Related]
7. Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells.
Hodge LS; Taub ME; Tracy TS
Biochem Pharmacol; 2011 Apr; 81(7):950-6. PubMed ID: 21291869
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Delauter BJ; Ramanathan RK; Egorin MJ; Stover LL; Zuhowski EG; Plunkett W; Zamboni WC
Pharmacotherapy; 2000 Oct; 20(10):1204-7. PubMed ID: 11034044
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
Sun Y; Zhen L; Peng Y; Wang J; Fei F; Aa L; Jiang W; Pei X; Lu L; Liu J; Wang G; Hao K
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 May; 1084():4-13. PubMed ID: 29558739
[TBL] [Abstract][Full Text] [Related]
10. Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS.
Honeywell RJ; Giovannetti E; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1203-13. PubMed ID: 22132976
[TBL] [Abstract][Full Text] [Related]
11. Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector.
Lin NM; Zeng S; Ma SL; Fan Y; Zhong HJ; Fang L
Acta Pharmacol Sin; 2004 Dec; 25(12):1584-9. PubMed ID: 15569401
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Egawa S; Unno M; Terasaki T
Pharm Res; 2012 Jul; 29(7):2006-16. PubMed ID: 22419259
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine.
Honeywell RJ; Ruiz van Haperen VW; Veerman G; Smid K; Peters GJ
Int J Biochem Cell Biol; 2015 Mar; 60():73-81. PubMed ID: 25562513
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
16. LC-MS/MS method for quantitation of gemcitabine and its metabolite 2',2'-difluoro-2'-deoxyuridine in mouse plasma and brain tissue: Application to a preclinical pharmacokinetic study.
Zhong B; Gibson EG; Davis A; Roussel MF; Stewart CF
J Pharm Biomed Anal; 2021 May; 198():114025. PubMed ID: 33744463
[TBL] [Abstract][Full Text] [Related]
17. A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.
Bapiro TE; Richards FM; Goldgraben MA; Olive KP; Madhu B; Frese KK; Cook N; Jacobetz MA; Smith DM; Tuveson DA; Griffiths JR; Jodrell DI
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1243-53. PubMed ID: 21431415
[TBL] [Abstract][Full Text] [Related]
18. Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients.
Specenier P; Guetens G; Dyck J; De Boeck G; Weyler J; Van den Weyngaert D; Aelbrecht K; Vermorken JB
Cancer Chemother Pharmacol; 2011 Jul; 68(1):185-91. PubMed ID: 20882386
[TBL] [Abstract][Full Text] [Related]
19. Sensitive liquid chromatography mass spectrometry (LC-MS) assay reveals novel insights on DNA methylation and incorporation of gemcitabine, its metabolite difluorodeoxyuridine, deoxyuridine, and RX-3117 into DNA.
Honeywell RJ; Sarkisjan D; Kathmann I; Kristensen MH; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):652-662. PubMed ID: 27906622
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
